Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria Component
Prevention of Intrauterine Growth Retardation in Hounde District, Burkina Faso: the Malaria Component
  • Phase

    Phase 4
  • Study Type

  • Status

    Completed No Results Posted
  • Study Participants

Our objective was to investigate the importance of malaria infection/disease during pregnancy and more particularly during the first trimester; we also looked at the maternal-foetal interactions and their influence on the subsequent child's response to malaria infections during the first year of life. This study was carried out !in the same population recruited for the IUGR study (NCT00642408).
A research project aiming at investigating the impact of multivitamin-mineral supplementation (MMS) during pregnancy on intra-uterin growth retardation was carried out in the Hounde district, an area not far from the Centre Muraz located in Bobo Dioulasso, and where malaria is endemic. Malaria during pregnancy increases the risk of low birth weight, infant mortality and morbidity during the first year of life by inducing growth retardation, prematurity and infant anaemia.

The administration of an antimalarial drug during pregnancy has a beneficial effect on the mother and child's health by preventing malaria infection and its consequences. However, most studies have been carried out during the second or third trimester of pregnancy: the effect of malaria infection during the first trimester on the mother's and child's health is unknown. It has been reported that even one single infection may have a significant impact on the outcome of pregnancy: if it is true, then early chemoprophylaxis may have an additional advantage.

An alternative approach is the administration of intermittent presumptive treatment, which may achieve equal efficacy to continuos chemoprophylaxis; however, no studies compared effective weekly malaria chemoprophylaxis with effective intermittent presumptive treatment. Moreover, the incidence of malaria clinical episodes during SP intermittent preventive treatment has never been investigated.

Therefore, this open label, factorial study was carried out in the same women recruited for the IUGR nutritional study (NCT00642408). Women receiving multiple micronutrients supplements (MMS) or dietary supplements (IFA) were further randomised in 2 groups: CQ weekly chemoprophylaxis or SP intermittent preventive treatment. The administration of treatment was directly observed.
Study Started
Jun 30
Primary Completion
Oct 31
Study Completion
Oct 31
Last Update
Sep 14

Dietary Supplement Multiple micronutrients supplements (MMS)

Vitamin A 800 mcg; vitamin E 10 mg; vitamin D 5 mcg; vitamin B1 1.4 mg; vitamin B2 1.4 mg;niacin 18 mg; vitamin B6 1.9 mg; vitamin B12 2.6 mcg; folic acid 400 mcg; vitamin C 70 mg; iron 30 mg; zinc 15 mg; copper 2 mg; selenium 65 mcg; iodine 150 mcg

  • Other names: UNIMMAP

Dietary Supplement Iron and folic acid (IFA)

Iron 60 mg and folic acid 400 mcg

Drug Chloroquine (CQ)

Tablets 100 mg of chloroquine base

Drug Sulphadoxyne-pyrimethamine (SP)


  • Other names: Fansidar

A1 Experimental

Multiple micronutrients supplements (MMS) and weekly chloroquine (CQ)

A2 Experimental

Multiple micronutrients supplements (MMS) and intermittent suplphadoxyne-pyrimethamine (SP)

B1 Experimental

Iron and folic acid (IFA) and weekly chloroquine (CQ)

B2 Experimental

Iron and folic acid (IFA) and intermittent sulphadoxyne-pyrimethamine (SP)


Inclusion Criteria:

15 to 44 years
living in the study area

Exclusion Criteria:

planning to move outside the district within two years
regularly using a contraceptive methods
already pregnant at the start of the trial
No Results Posted